CT-guided PCI matches IVUS outcomes with faster procedures and less contrast, changing treatment plans in 70% of cases.

A landmark P4 randomized trial showed that CT-guided percutaneous coronary intervention (PCI) delivers clinical outcomes comparable to the gold-standard intravascular ultrasound (IVUS) at one year, while reducing procedure time by 27% and contrast use by 12%. The NAVIGATE-PCI registry further revealed that Heartflow's AI-powered PCI Navigator led to treatment plan changes in about 70% of patients, improving stent length and lesion preparation decisions. These findings support a shift toward non-invasive CT-guided PCI planning, enhancing precision and efficiency in coronary interventions. This advancement could make pre-procedural CT imaging a routine part of cardiac catheterization lab practice.

Heartflow Inc. (HTFL) shares are trading at USD 59.05 on Pluang as of Nov 02, 2026 02:02 WIB, down 2.45% in the last day. The stock's market cap stands at $5.14 billion, reflecting its significant presence in the health sector. This trading data provides context to the reported advancements in CT-guided PCI and AI-driven PCI planning highlighted in the recent P4 trial and NAVIGATE-PCI registry.